If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
=== Gene cluster === The study of the genetic cluster encoding the biosynthesis of teicoplanin identified 49 putative open reading frames (ORFs) involved in the compound's biosynthesis, export, resistance, and regulation. Thirty-five of these ORFs are similar to those found in other glycopeptide gene clusters. The function of each of these genes is described by Li and co-workers. A summary of the gene layout and purpose is shown below. Gene layout. The genes are numbered. The letters L and R designate transcriptional direction. The presence of the * symbol means a gene is found after NRPs, which are represented by A, B, C, and D. Based on the figure from: Li, T-L.; Huang, F.; Haydock, S. F.; Mironenko, T.; Leadlay, P. F.; Spencer, J. B. Chemistry & Biology. 2004, 11, p. 109. [11-L] [10-L] [9-R] [8-R] [7-R] [6-R] [5-R] [4-L][3-L] [2-L] [1-R] [A-R] [B-R] [C-R] [D-R] [1*-R] [2*-R] [3*-R] [4*-R] [5*-R] [6*-R] [7*-R] [8*-R] [9*-R] [10*-R] [11*-R] [12*-R] [13*-R] [14*-R] [15*-R] [16*-R] [17*-R] [18*-R] [19*-R] [20*-R] [21*-R] [22*-R] [23*-R] [24*-R] [25*-L] [26*-L] [27*-R] [28*-R] [29*-R] [30*-R][31*-R] [32*-L] [33*-L] [34*-R]
Peptides can perform interactions with proteins and other macromolecules. They are responsible for numerous important functions in human cells, such as cell signaling, and act as immune modulators. Indeed, studies have reported that 15-40% of all protein–protein interactions in human cells are mediated by peptides. Additionally, it is estimated that at least 10% of the pharmaceutical market is based on peptide products.
== History == Viscofan was founded in 1975, which is also when it began producing and selling its products. In 1988, Viscofan acquired the food group IAN (Industrias Alimentarias de Navarra), aiming to improve its presence in the Spanish market. Viscofan continued its international expansion by acquiring the German company Naturin GmbH & Co. in 1990 and opening new commercial offices overseas. Additional acquisitions included Gamex in the Czech Republic (1995), Trificel in São Paulo, Brazil (1995), Koteksprodukt AD in Serbia (2005), and the assets of Sweden's AB Tripasin (2005). In 2006, Viscofan broadened its footprint in the Americas by acquiring the U.S. and Mexican assets of Teepak. In 2008, Viscofan expanded its cogeneration plant in Spain. That same year, the company launched Viscofan Bioengineering, a business unit that merges bioscience and engineering to develop collagen-based products intended for tissue repair. The Bioengineering unit is located in Weinheim (Germany), where Viscofan also maintains a production site for collagen casings and an additional cleanroom facility for manufacturing medical-grade collagen materials. In 2009, Viscofan established Viscofan Technology (Suzhou) Co. Ltd. in China. The following year, it opened a converting plant in the country. In 2012, the company created Viscofan Uruguay S.A., followed by the opening of a collagen extrusion plant in China in 2013 and another extrusion facility in Uruguay in 2014. In 2015, Viscofan sold the IAN Group to focus on its casings business.
Sources: en.wikipedia.org
Their vows make everyone forget the "dire situation" for a moment, until Ari suddenly collapses. Ari succumbs to the cancer and his death aired on 7 March 2022. After the episode was broadcast aired, Kipa-Williams took to his Instagram account to post a thank you message to the show's cast, crew, and fans for their support. He said "This Iconic Ozzie TV show took risks. I'm honoured to have co-created Māori cultural storylines, and will forever be proud of those scenes that made it to screen.. it was true teamwork.. My hope is this opens the door for more diversity. Thank you for everything Ariki Wiremu Parata, you taught me a lot. I'm gonna miss you." The character made one final appearance on 15 March 2022, as Ari appears to Mia in a dream. The following year, Kipa-Williams revealed that he quit Home and Away because of "a calling" to the Māori culture. He moved back to Aotearoa, where he bought a farm and began lessons in te reo in order to become more fluent in the language.
The large intestine contains multiple types of bacteria, and other microorganisms that can break down molecules the human body cannot process alone, demonstrating a symbiotic relationship. These microbes are responsible for gas production at host–pathogen interface, which is released as flatulence. Intestinal bacteria can also participate in biosynthesis reactions. For example, certain strains in the large intestine produce vitamin B12; an essential compound in humans for things like DNA synthesis and red blood cell production. However, the primary function of the large intestine is water absorption from digested material (regulated by the hypothalamus) and the reabsorption of sodium and nutrients. Beneficial intestinal bacteria compete with potentially harmful bacteria for space and nutrients, as the intestinal tract has limited resources. A ratio of 80–85% beneficial to 15–20% potentially harmful bacteria is proposed for maintaining homeostasis. An imbalanced ratio results in dysbiosis.
When walking at a leisurely pace on level ground (no incline), but there is loose gravel or sand, long grass, snow, mud, or walking into a headwind, that added resistance (requiring more effort) makes the activity more reliant on muscle glycogen also. These and other surfaces, such as ice, can make you tense your muscles (which is anearobic requiring muscle glycogen) as you protect yourself from slipping or falling. Those with muscle glycogenoses can maintain a healthy life of exercise by learning activity adaptations, utilizing the bioenergetic systems that are available to them. Depending on the type of activity and whether they are in second wind, they slow their pace or rest briefly when need be, to make sure not to empty their "ATP reservoir."
On 3 January 2024, UNICEF chief Catherine M. Russell stated many children in Gaza were facing severe acute malnutrition. On 5 January, UNICEF found 90 percent of children under the age of two were eating two or fewer food groups a day. On 3 February, Hani Mahmoud, an Al Jazeera journalist in Rafah, stated, "We’re seeing children roaming around in Rafah looking for scraps of food." In early January 2024 UNICEF reported that around 90% of children in Gaza under 2 were subjected to severe food poverty, which had jumped from 80% about two weeks prior. Price jumps have also been seen by those attempting to purchase food, with a caregiver purchasing through a procurement company infant formula which had cost him $1,680 before the war, but paying $2,160 in February 2024. The United Nations stated on 10 February 2024 that 10 percent of children under five-years-old were suffering from acute malnourishment. One mother reported feeding her newborn using date paste. On 19 February 2024, UNICEF found that nearly 16 percent of children in northern Gaza under two-years-old were "acutely malnourished", with 3 percent suffering from severe wasting. In early March 2024 UNICEF reported that over 90% of children aged 6–23 months and pregnant or breastfeeding women face severe food poverty with access to two or fewer food groups a day. Child malnutrition is varied throughout Gaza, with northern Gaza experiencing worse food shortages then southern Gaza leading to a child malnutrition rate three times higher according to the WHO.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.